Q: What is Kygevvi used for?

Kygevvi is used to treat primary immunodeficiency .

Q: How does Kygevvi work?

Mechanism of Action Kygevvi is a substrate replacement therapy used to treat thymidine kinase 2 deficiency (TK2d), a rare genetic disorder. In people with this condition, a specific enzyme called thymidine kinase 2 does not work correctly. This enzyme is responsible for creating the building blocks, known as nucleotides, that the body needs to build and maintain mitochondrial DNA. Mitochondria are often called the powerhouses of the cell because they produce the energy needed for organs and muscles to function. Without enough mitochondrial DNA, these powerhouses cannot work properly, leading to muscle weakness and other symptoms. Kygevvi contains two active ingredients, doxecitine and doxribtimine, which are nucleosides. When taken, these ingredients work by: Acting as alternative building blocks for mitochondrial DNA. Bypassing the faulty enzyme to help the body produce the necessary nucleotides. Supporting the maintenance and repair of mitochondrial DNA within the cells. By restoring these building blocks, the medication helps improve the function of mitochondria, which is essential for maintaining muscle strength and overall energy levels in patients with TK2d.

Q: What are the active ingredients in Kygevvi?

The active ingredients in Kygevvi are Doxecitine and Doxribtimine .

Q: What are the side effects of Kygevvi?

Common side effects of Kygevvi may include Not FDA approved . No reliable, publicly available data defining common side effects. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Kygevvi?

Kygevvi belongs to the SGLT2 inhibitor and biguanide combination drug class.

Q: What is the dosage of Kygevvi and how do I take it?

Administration Instructions Kygevvi is supplied as a powder that must be mixed with a liquid before use. Common liquids used for mixing include water, milk, or infant formula. Once prepared, the solution can be taken by mouth or administered through a feeding tube, such as a gastrostomy tube (G-tube). The medication is typically taken three times per day. It may be taken with or without food. It is important to follow the specific preparation and administration steps provided by a healthcare professional to ensure the full dose is received. Missed Dose If a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take two doses at once to make up for a missed dose.

Q: Is Kygevvi safe during pregnancy and breastfeeding?

Pregnancy It is not known whether Kygevvi can cause fetal harm when administered to a pregnant woman. There are no available data on the use of this medication in humans during pregnancy, and animal reproduction studies have not been conducted to evaluate potential risks. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of this treatment with your healthcare provider. Breastfeeding There is no information regarding the presence of Kygevvi in human milk, its effects on a breastfed infant, or its impact on milk production. Because the risks are unknown, patients who are breastfeeding or planning to breastfeed should consult with their doctor to determine the most appropriate course of action.

Q: What forms and strengths does Kygevvi come in?

Available Forms Kygevvi is supplied as oral granules. It is a combination product containing two separate active ingredients that are packaged together: Doxecitine Doxribtimine These granules are intended to be taken by mouth or administered through an enteral feeding tube, such as a gastrostomy tube (G-tube) or jejunostomy tube (J-tube), after being mixed with liquid or soft food.

Q: What is the FDA approval status of Kygevvi?

FDA Approval Status Kygevvi (doxecitine and doxribtimine) received FDA approval on September 27, 2024. It is the first medication approved to treat thymidine kinase 2 deficiency (TK2d), a rare and often fatal mitochondrial disease that causes progressive muscle weakness. The approval covers use in both pediatric and adult patients. Regulatory Designations The FDA utilized several programs to accelerate the review of Kygevvi due to the serious nature of TK2d and the lack of existing treatments. These included: Breakthrough Therapy designation: Granted to expedite the development of drugs for serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies. Orphan Drug designation: Provided to support the development of treatments for rare diseases affecting fewer than 200,000 people in the United States. Priority Review: Assigned to applications for drugs that would provide significant improvements in the safety or effectiveness of the treatment of serious conditions. Safety Oversight The regulatory approval was based on clinical data showing improvements in motor function and survival compared to the natural progression of the disease. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this medication.

Question 1

What is Kygevvi?

Accepted Answer

Kygevvi is a combination of two pyrimidine nucleosides, doxecitine and doxribtimine, that acts as a replacement therapy. It is designed to provide the body with specific building blocks that are essential for the maintenance and stability of mitochondrial DNA.

This medication works by supplementing the levels of these components when the body cannot produce them in sufficient amounts. By restoring these building blocks, the therapy helps support the normal function and energy production of cells throughout the body.

Question 2

What is Kygevvi used for?

Accepted Answer

Kygevvi is used to treat primary immunodeficiency.

Question 3

How does Kygevvi work?

Accepted Answer

Mechanism of Action

Kygevvi is a substrate replacement therapy used to treat thymidine kinase 2 deficiency (TK2d), a rare genetic disorder. In people with this condition, a specific enzyme called thymidine kinase 2 does not work correctly. This enzyme is responsible for creating the building blocks, known as nucleotides, that the body needs to build and maintain mitochondrial DNA.

Mitochondria are often called the powerhouses of the cell because they produce the energy needed for organs and muscles to function. Without enough mitochondrial DNA, these powerhouses cannot work properly, leading to muscle weakness and other symptoms.

Kygevvi contains two active ingredients, doxecitine and doxribtimine, which are nucleosides. When taken, these ingredients work by:

Acting as alternative building blocks for mitochondrial DNA.
Bypassing the faulty enzyme to help the body produce the necessary nucleotides.
Supporting the maintenance and repair of mitochondrial DNA within the cells.

By restoring these building blocks, the medication helps improve the function of mitochondria, which is essential for maintaining muscle strength and overall energy levels in patients with TK2d.

Question 4

What are the active ingredients in Kygevvi?

Accepted Answer

The active ingredients in Kygevvi are Doxecitine and Doxribtimine.

Question 5

What are the side effects of Kygevvi?

Accepted Answer

Common side effects of Kygevvi may include Not FDA approved. No reliable, publicly available data defining common side effects.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Kygevvi?

Accepted Answer

Kygevvi belongs to the SGLT2 inhibitor and biguanide combination drug class.

Question 7

What is the dosage of Kygevvi and how do I take it?

Accepted Answer

Administration Instructions

Kygevvi is supplied as a powder that must be mixed with a liquid before use. Common liquids used for mixing include water, milk, or infant formula. Once prepared, the solution can be taken by mouth or administered through a feeding tube, such as a gastrostomy tube (G-tube).

The medication is typically taken three times per day. It may be taken with or without food. It is important to follow the specific preparation and administration steps provided by a healthcare professional to ensure the full dose is received.

Missed Dose

If a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take two doses at once to make up for a missed dose.

Question 8

Is Kygevvi safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known whether Kygevvi can cause fetal harm when administered to a pregnant woman. There are no available data on the use of this medication in humans during pregnancy, and animal reproduction studies have not been conducted to evaluate potential risks. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of this treatment with your healthcare provider.

Breastfeeding

There is no information regarding the presence of Kygevvi in human milk, its effects on a breastfed infant, or its impact on milk production. Because the risks are unknown, patients who are breastfeeding or planning to breastfeed should consult with their doctor to determine the most appropriate course of action.

Question 9

What forms and strengths does Kygevvi come in?

Accepted Answer

Available Forms

Kygevvi is supplied as oral granules. It is a combination product containing two separate active ingredients that are packaged together:

Doxecitine
Doxribtimine

These granules are intended to be taken by mouth or administered through an enteral feeding tube, such as a gastrostomy tube (G-tube) or jejunostomy tube (J-tube), after being mixed with liquid or soft food.

Question 10

What is the FDA approval status of Kygevvi?

Accepted Answer

FDA Approval Status

Kygevvi (doxecitine and doxribtimine) received FDA approval on September 27, 2024. It is the first medication approved to treat thymidine kinase 2 deficiency (TK2d), a rare and often fatal mitochondrial disease that causes progressive muscle weakness. The approval covers use in both pediatric and adult patients.

Regulatory Designations

The FDA utilized several programs to accelerate the review of Kygevvi due to the serious nature of TK2d and the lack of existing treatments. These included:

Breakthrough Therapy designation: Granted to expedite the development of drugs for serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies.
Orphan Drug designation: Provided to support the development of treatments for rare diseases affecting fewer than 200,000 people in the United States.
Priority Review: Assigned to applications for drugs that would provide significant improvements in the safety or effectiveness of the treatment of serious conditions.

Safety Oversight

The regulatory approval was based on clinical data showing improvements in motor function and survival compared to the natural progression of the disease. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this medication.

Question 11

What should I know about Kygevvi and cost?

Accepted Answer

Insurance and Out-of-Pocket Costs

The price of Kygevvi is primarily determined by your health insurance plan. Because it is a specialized treatment for a rare condition, most insurance providers will require a prior authorization process before covering the medication. Your total out-of-pocket cost will depend on your plan's deductible, copayment, or coinsurance requirements.

Specialty Pharmacy Access

Kygevvi is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These pharmacies are equipped to handle medications for rare diseases and can provide specific pricing information based on the weight-based dosage prescribed by a healthcare provider.

Financial Assistance

For medications used to treat rare mitochondrial diseases like thymidine kinase 2 deficiency (TK2d), there are often patient support programs available. These programs may include:

Copay Assistance: Programs designed to help patients with commercial insurance reduce their out-of-pocket expenses.
Patient Assistance Programs: Support for individuals who are uninsured or have limited insurance coverage.
Support Services: Assistance with navigating insurance approvals and coordinating delivery through specialty pharmacies.

Patients and caregivers should speak with their medical team or the drug manufacturer to learn about specific financial aid options and to get an accurate estimate of the cost.

Kygevvi

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Kygevvi

Hospitals.net Disclosure